SOPHiA GENETICS announced an expanded integration of Genomenon's Mastermind® Genomic Intelligence Platform into its Alamut™ Visual Plus, aiming to support data-driven outcomes in rare disease and oncology. This collaboration is designed to empower researchers and clinical geneticists by accelerating variant interpretation for rare disorders and cancers.
The integration significantly enhances variant curation and interpretation by connecting Alamut™ Visual Plus, an advanced decision-support tool, to Mastermind's vast library of scientific research. Mastermind provides comprehensive curated evidence for genomic data, including indexed content from over 10 million full-text articles, offering critical insights even for rare variants with limited existing research.
This partnership allows clinicians and researchers to more efficiently assess the pathogenicity of variants, enabling informed decisions with greater confidence. It also benefits SOPHiA GENETICS by providing its customers with a more comprehensive understanding of detected variants within a seamless, single platform, while broadening Genomenon's reach through SOPHiA's global network.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.